The role of matrix metalloproteinase 9 in fibrosis diseases and its molecular mechanisms
- PMID:38181715
- DOI: 10.1016/j.biopha.2023.116116
The role of matrix metalloproteinase 9 in fibrosis diseases and its molecular mechanisms
Abstract
Fibrosis is a process of tissue repair that results in the slow creation of scar tissue to replace healthy tissue and can affect any tissue or organ. Its primary feature is the massive deposition of extracellular matrix (mainly collagen), eventually leading to tissue dysfunction and organ failure. The progression of fibrotic diseases has put a significant strain on global health and the economy, and as a result, there is an urgent need to find some new therapies. Previous studies have identified that inflammation, oxidative stress, some cytokines, and remodeling play a crucial role in fibrotic diseases and are essential avenues for treating fibrotic diseases. Among them, matrix metalloproteinases (MMPs) are considered the main targets for the treatment of fibrotic diseases since they are the primary driver involved in ECM degradation, and tissue inhibitors of metalloproteinases (TIMPs) are natural endogenous inhibitors of MMPs. Through previous studies, we found that MMP-9 is an essential target for treating fibrotic diseases. However, it is worth noting that MMP-9 plays a bidirectional regulatory role in different fibrotic diseases or different stages of the same fibrotic disease. Previously identified MMP-9 inhibitors, such as pirfenidone and nintedanib, suffer from some rather pronounced side effects, and therefore, there is an urgent need to investigate new drugs. In this review, we explore the mechanism of action and signaling pathways of MMP-9 in different tissues and organs, hoping to provide some ideas for developing safer and more effective biologics.
Keywords: Antifibrosis; Fibrosis; Matrix metalloproteinase-9; Signal pathway.
Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing conflicts of interest or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
- Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis.Shan L, Wang F, Zhai D, Meng X, Liu J, Lv X.Shan L, et al.Biomed Pharmacother. 2023 May;161:114472. doi: 10.1016/j.biopha.2023.114472. Epub 2023 Mar 2.Biomed Pharmacother. 2023.PMID:37002573Review.
- Evaluation of inductive effects of different concentrations of cyclosporine A on MMP-1, MMP-2, MMP-3, TIMP-1, and TIMP-2 in fetal and adult human gingival fibroblasts.Nazemisalman B, Sajedinejad N, Darvish S, Vahabi S, Gudarzi H.Nazemisalman B, et al.J Basic Clin Physiol Pharmacol. 2019 Mar 26;30(3). doi: 10.1515/jbcpp-2018-0176.J Basic Clin Physiol Pharmacol. 2019.PMID:30913036
- Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.Truter SL, Catanzaro DF, Supino PG, Gupta A, Carter J, Herrold EM, Dumlao TF, Borer JS.Truter SL, et al.Cardiology. 2009;113(3):161-8. doi: 10.1159/000187723. Epub 2009 Jan 8.Cardiology. 2009.PMID:19129699
- Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.Krebber MM, van Dijk CGM, Vernooij RWM, Brandt MM, Emter CA, Rau CD, Fledderus JO, Duncker DJ, Verhaar MC, Cheng C, Joles JA.Krebber MM, et al.Int J Mol Sci. 2020 Sep 14;21(18):6742. doi: 10.3390/ijms21186742.Int J Mol Sci. 2020.PMID:32937927Free PMC article.
- Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases.Kim IS, Yang WS, Kim CH.Kim IS, et al.Curr Med Chem. 2023;30(18):2075-2112. doi: 10.2174/0929867329666220823112731.Curr Med Chem. 2023.PMID:36017851Review.
Cited by
- Enrichment of Fat Graft with Association of ASC and Nanofat in an Animal Model.Camargo CP, Barbosa EF, Chammas MC, Silveira HB, Santos DLS, Furuya TK, Alves MJF, Uno M, Altran SC, Gemperli R.Camargo CP, et al.Aesthetic Plast Surg. 2025 Feb;49(3):908-916. doi: 10.1007/s00266-024-04322-5. Epub 2024 Oct 14.Aesthetic Plast Surg. 2025.PMID:39402194
- A New Rat Model of Sacral Cord Injury Producing a Neurogenic Bladder and Its Functional and Mechanistic Studies.Bai K, Hou Y, Zhang Z, Yuan F, Huang X, Liu P, Zou X, Sun J.Bai K, et al.Biomolecules. 2024 Sep 9;14(9):1141. doi: 10.3390/biom14091141.Biomolecules. 2024.PMID:39334907Free PMC article.
- Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model.Kostadinova R, Ströbel S, Chen L, Fiaschetti-Egli K, Gadient J, Pawlowska A, Petitjean L, Bieri M, Thoma E, Petitjean M.Kostadinova R, et al.Sci Rep. 2024 Mar 11;14(1):5885. doi: 10.1038/s41598-024-55438-2.Sci Rep. 2024.PMID:38467661Free PMC article.
- Hypoxia and aging: molecular mechanisms, diseases, and therapeutic targets.Nisar A, Khan S, Li W, Hu L, Samarawickrama PN, Gold NM, Zi M, Mehmood SA, Miao J, He Y.Nisar A, et al.MedComm (2020). 2024 Oct 15;5(11):e786. doi: 10.1002/mco2.786. eCollection 2024 Nov.MedComm (2020). 2024.PMID:39415849Free PMC article.Review.
- Integrating Natural Deep Eutectic Solvents into Nanostructured Lipid Carriers: An Industrial Look.Schuh L, Salgado LA, Piau TB, Silveira AP, Leal C, Romera LF, Radicchi MA, Santos MMS, Falcao L, Grisolia CK, Gris EF, Muehlmann LA, Báo SN, Mello VC.Schuh L, et al.Pharmaceuticals (Basel). 2024 Jun 28;17(7):855. doi: 10.3390/ph17070855.Pharmaceuticals (Basel). 2024.PMID:39065706Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Miscellaneous